Skip to main content
Clinical Trials/NCT02351089
NCT02351089TerminatedNot Applicable

Probiotics in Radiation-treated Gynecologic Cancer

Probi AB1 site in 1 country97 target enrollmentStarted: February 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Probi AB
Enrollment
97
Locations
1
Primary Endpoint
Change in incidence of loose/watery stools

Study Overview

Brief Summary

The aim of the current Project is to study the efficacy of a probiotic Product in reducing the symptoms of gastrointestinal toxicity linked to the irradiation of gynecologic cancer.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women diagnosed with cancer in the small pelvis and waiting to receive radiotherapy either as a primary or as a secondary treatment following surgery. Chemotherapy may or may not be part of the treatment regimen.
  • Age, older than 18 years old.
  • Agreement for participation in the study by signed written informed consent.

Exclusion Criteria

  • Previously treated with irradiation of the pelvic area.
  • Reluctance to refrain from using other probiotic products during the participation in the study.

Outcomes

Primary Outcomes

Change in incidence of loose/watery stools

Time Frame: Baseline and 10 weeks later

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Probi AB
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials